119-HR-5865 Journalist Public Summary
119 · HR 5865 Thalidomide Survivors Compensation Act of 2025
Creates a federal program at HHS to give a one‑time $150,000, tax‑free payment to eligible U.S. thalidomide survivors, with potential for additional help later and protections so the payment doesn’t reduce means‑tested benefits; introduced Oct 28, 2025 and now in House committees.
Headline Summary
A House bill would set up a federal program to pay eligible U.S. thalidomide survivors a one‑time $150,000, tax‑free benefit and allow for additional support later, without affecting eligibility for means‑tested benefits.
What It Does
H.R. 5865 creates a Thalidomide Survivors Compensation Program at the Department of Health and Human Services. Within one year of enactment, HHS must open a petition process reviewed by an expert panel (medical, legal, and survivor representatives). If the panel confirms injury from in‑utero thalidomide exposure, the Secretary pays a flat $150,000 per person. Payments are excluded from federal income tax and must be ignored when agencies calculate eligibility for means‑tested programs. People can file only once and must be U.S. citizens or permanent residents both now and at the time of exposure. Petitions close May 31, 2034. HHS must report to Congress annually and may, subject to appropriations, issue additional compensation to address ongoing needs. Funding is authorized in “such sums as necessary” for fiscal years 2028–2034.
- Findings section cites an estimated worldwide toll of 10,000+ birth defects/deaths and suggests roughly 100 U.S. survivors remain.
- Purpose is to support survivors’ independence and dignity through compensation and potential follow‑on assistance.
Who’s For It
- Sponsor: Rep. Jefferson Van Drew (NJ).
- Formal cosponsors or outside endorsements aren’t listed in the provided text. Likely supporters include thalidomide survivors and disability‑rights advocates who argue a federal payment helps with long‑term medical, accessibility, and care costs and aligns the U.S. with dozens of countries that already compensate survivors.
Who’s Against It
- No formal opposition is included in the provided materials. Potential concerns could include:
- Cost uncertainty: the bill authorizes “such sums as necessary” through FY2028–2034 without a scored price tag.
- Proof hurdles: documenting mid‑20th‑century exposure and linking injuries could be hard for some applicants.
- Eligibility limits: requiring U.S. citizenship or permanent residency at the time of exposure may exclude people who later became residents.
- Program design questions: a flat payment may not match widely varying medical needs; the bill anticipates this with possible additional payments, but those depend on future appropriations.
What’s Next
Status as of October 30, 2025: Introduced on October 28, 2025 and referred to the Judiciary Committee and several others (including Ways and Means; Energy and Commerce; Veterans’ Affairs, among others). The bill would need committee hearings/markups, a House vote, Senate passage, and the President’s signature to become law.
Discussion